Steve J. Offord

Psychiatry University of Pennsylvania, Philadelphia, PA, United States 
"Steve Offord"
Mean distance: 18.02 (cluster 19)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Wilson M, Gutierrez B, Offord SJ, et al. (2016) Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5: 212273
Karson C, Duffy RA, Eramo A, et al. (2016) Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment. 12: 57-67
Citrome L, Eramo A, Francois C, et al. (2015) Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment. 11: 3095-104
Kamat SA, Offord S, Docherty J, et al. (2015) Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context. 4
Bera R, Offord S, Zubek D, et al. (2014) Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. Journal of Clinical Psychopharmacology. 34: 30-5
Offord S, Lin J, Wong B, et al. (2013) Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Community Mental Health Journal. 49: 625-9
Kirson NY, Weiden PJ, Yermakov S, et al. (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. The Journal of Clinical Psychiatry. 74: 568-75
Lin J, Wong B, Offord S, et al. (2013) Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. The Journal of Behavioral Health Services & Research. 40: 355-66
Offord S, Lin J, Mirski D, et al. (2013) Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Advances in Therapy. 30: 286-97
Bera R, Offord S, Zubek D, et al. (2013) Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. Journal of Medical Economics. 16: 522-8
See more...